Archemix Corp., a Cambridge, Mass.-based developer of aptamer-based therapeutics, has lost its bid to go public via a reverse merger with NitroMed Inc. (Nasdaq: NTMD), after NitroMed accepted a richer offer from Deerfield Management. Archemix received a $1.5 milion termination fee.
